Trials & Filings

OncoMed Begins Third Pancreatic Cancer Trial

Combo with Abraxane and gemcitabine in collaboration with Bayer

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

OncoMed Pharmaceuticals has started a Phase Ib trial of its first-in-class Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer. This trial is the third of three Phase Ib trials for vantictumab initiated this year as part of OncoMed’s collaboration with Bayer Pharma AG. The multi-center trial is a dose-escalation study that will evaluate safety of vantictumab in combination with Abra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters